Clinical Trials Browser

Phase 1 × Recurrence × Brentuximab Vedotin × Clear all

NCT03302728 2022-05-19

EpiBrentlen

Phase 1 Completed

DermatologicLymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02780011 2018-07-27

AD3LE

Phase 1 Withdrawn

Recurrence

NCT02280993 2018-03-13

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Phase 1 Unknown

Hodgkin Disease, Recurrence